Results 101 to 110 of about 1,140,114 (148)

From Evidence Generation to Decision Making: Completing the Clinical Pharmacology Pathway. [PDF]

Clin Pharmacol Ther
Rowland Yeo K.
europepmc   +1 more source

Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis. [PDF]

Clin Pharmacol Ther
Krishna R.
europepmc   +1 more source

Current status of extracellular vesicle technology in industrialization and commercialization. [PDF]

Discov Nano
Wu Y.
europepmc   +1 more source

Pharmaceutical Industry Perspectives on Exposure-Response Confounding in Large Molecule Therapeutics: Results From an IQ Consortium Survey. [PDF]

CPT Pharmacometrics Syst Pharmacol
Salama E, Lamba M, Ait-Oudhia S, Wang E, Semiond D, Li Z, Long T, Suryawanshi S, Arrington L, Gao W, Guan X, Giovinazzo H, Miles D, Turner DC.   +13 more
europepmc   +1 more source

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in <i>HER2</i>-Amplified Metastatic Colorectal Cancer. [PDF]

JCO Precis Oncol
Garcia-Pastor P, Ros J, Baraibar I, Salva F, Salva C, Garcia A, Vaghi C, Tabernero J, Vivancos A, Elez E.   +9 more
europepmc   +1 more source

Decentralised oncology trials: decentralisation as a tool, not the goal. [PDF]

BMJ Oncol
Cohen JE, Taylor N, Webster AC, Liu J.
europepmc   +1 more source

Relative Mutant Allele Frequency Role in ctDNA-Guided Anti-Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer. [PDF]

JCO Precis Oncol
Yaringaño J, García Pastor P, Salva F, Saoudi González N, Ros J, Baraibar I, Rodríguez Castells M, Salva de Torres C, Mascaró Baselga P, García A, Vaghi C, Vivancos A, Tabernero J, Elez E.   +13 more
europepmc   +1 more source